CDK4/6 Inhibition Overcomes Drug Resistance in HER2+ Breast Cancer
- PMID: 27012828
- DOI: 10.1158/2159-8290.CD-RW2016-054
CDK4/6 Inhibition Overcomes Drug Resistance in HER2+ Breast Cancer
Abstract
Resistance to targeted therapies in HER2(+) breast cancer is mediated by cyclin D1 and CDK4.
©2016 American Association for Cancer Research.
Comment on
-
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Cancer Cell. 2016 Mar 14;29(3):255-269. doi: 10.1016/j.ccell.2016.02.006. Cancer Cell. 2016. PMID: 26977878 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous